Printables – Your selection
Issue Health Sciences
The following publications match your selection:
 | Beyond Borders 2010 – Global Biotechnology Report
Hardcopy orders only inside Switzerland
Price:
CHF 50
per piece
| |
 | Beyond Borders 2010 – Global Biotechnology Report
Please submit the form to receive the download link for the pdf of the report.
Price:
free
| |
 | Swiss Biotech Report 2010
The Swiss biotech industry has handled the challenges of the global financial downturn remarkably well and remains dynamic, thanks to a traditionally high standard of living, a sustainable economy and an array of national initiatives supporting its high-tech industries. While the financial crisis has not left Switzerland untouched, Switzerland generally was not as hard hit as other highly industrialized countries.
 2273 kB
| |
 | Swiss Biotech Report – Update 2009
The Swiss biotech sector continued growing in 2008. Although risk capital proved harder to come by than in the record year of 2007, the sector nonetheless managed to expand by achieving higher sales, licensing new products and starting up new companies.
1398 kB
| |
 | Swiss Medtech Report 2008
The second Swiss Medtech Report reveals that the medtech industry in Switzerland has increased its share of the growing global medical technology market. Medtech is one of the fastest growing Swiss sectors. Annual growth rates in the past two years have increased to 25-30%. Studies suggest that therapy systems, implants and prosthetics are the fastest growing fields and these are the focus areas of many Swiss companies.
1711 kB
| |
 | Swiss Biotech Report 2008
Swiss biotechnology saw new records set in 2007 with regard to total revenue, R&D success and new capital raised. These are only some of the highlights in another strong biotech-year.
3320 kB
| |
 | Swiss Biotech Report 2007
The future of the Swiss biotech industry remains promising: turnover grew by a further significant 7.8% and the sector made CHF 917 million profit in 2006. The fourth Swiss Biotech Report, presented in Zurich today, outlines the reasons behind this success.
2757 kB
| |
 | Swiss Biotech Report 2006
The third and updated Swiss Biotech Report was presented to the media in Zurich today. Edited by project partners Ernst & Young, SWX Swiss Exchange, the State Secretariat for Economic Affairs (seco), the Swiss Innovation Promotion Agency (KTI/CTI), the Swiss Federal Institute for Intellectual Property, Swiss Biotech – the marketing organisation for the biotech industry as well as the Swiss Private Equity and Corporate Finance Organization (SECA), the report has become an important instrument ...
2233 kB
| |
 | Swiss Medtech Report 2005
The first Swiss Medtech Report, issued by the project partners Ernst & Young, SWX Swiss Exchange, the State Secretariat for Economic Affairs (seco), the Innovation Promotion Agency KTI/CTI, Osec Business Network Switzerland, the Institute of Intellectual Property and Swiss Medtech shows that the Swiss Medtech industry has been able to further develop its dominant position thanks to economically beneficial underlying conditions, great expertise and the excellent networking of research and the ...
1449 kB
| |
 | Swiss Biotech Report 2005
The second and updated Swiss Biotech Report was presented to the media in Zurich today. Edited by project partners Ernst & Young, SWX Swiss Exchange, the State Secretariat for Economic Affairs (seco), the Swiss Innovation Promotion Agency (KTI/CTI), and Swiss Biotech, the marketing organisation for the biotech industry, the report confirms that the Swiss biotech industry has maintained and even expanded its leading position in Europe despite the current round of consolidation.
1241 kB
| |
 | Swiss Biotech Report
With a highly educated and skilled workforce, Switzerland is also home to approximately 250 small and medium-sized enterprises with activities in the biotech area. Having identified biotechnology as a key factor for future development, the Swiss Government has undertaken various efforts to create an attractive business environment in this field. The proximity to the prestigious Swiss chemical and pharmaceutical companies and to national and international knowledge clusters makes Switzerland ...
1578 kB
| |
 | «Integration» – European Life Sciences Report 2001
This report covers only Entrepreneurial Life Science Companies (ELISCOs). ELISCOs are defined as companies that use modern biological techniques to develop products or services to serve the needs of human healthcare or animal health, agriculturtal productivity, food processing, renewable resources or environmental affairs. ORDER THIS REPORT.
Price:
free
| |
 | «Evolution» – European Life Sciences Report 2000
Der Biotech-Markt gehört zu den wichtigsten Emerging Markets der Gegenwart.Heute entwickelte Medikamente und Verfahren werden einen entscheidenden Einfluss auf die Life Sciences-Industrie von morgen haben. BESTELLEN SIE DEN REPORT.
184 kB
Price:
free
| |
|
|
|
| Related content |
| Periodicals |
|
Magazines
Annual Reports
Newsletter
|
|
|
|
|